This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ebihara, K. Articles by Nakao, K. Search for Related Content PubMed PubMed Citation Articles by Ebihara, K. Articles by Nakao, K. Related Collections Diabetes and Insulin Obesity

Efficacy and Safety of Leptin-Replacement Therapy and Possible Mechanisms of Leptin Actions in Patients with Generalized Lipodystrophy

Department of Medicine and Clinical Science (K.E., T.K., M.H., H.M., F.M., N.K., T.T., H.C., T.M., T.H., K.H., Y.O., K.N.), Kyoto University Graduate School of Medicine, and Department of Clinical Trial Management (M.F.), Translational Research Center, Kyoto University Hospital, Kyoto 606-8507, Japan; and Amgen Inc. (A.M.D.), Thousand Oaks, California 91319

Address all correspondence and requests for reprints to: Ken Ebihara or Kazuwa Nakao, Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. E-mail: Kebihara{at}kuhp.kyoto-u.ac.jp or Nakao{at}kuhp.kyoto-u.ac.jp.

Background: Lack of leptin is implicated in insulin resistance and other metabolic abnormalities in generalized lipodystrophy; however, the efficacy, safety, and underlying mechanisms of leptin-replacement therapy in patients with generalized lipodystrophy remain unclear.

Methods: Seven Japanese patients with generalized lipodystrophy, two acquired and five congenital type, were treated with the physiological replacement dose of recombinant leptin during an initial 4-month hospitalization followed by outpatient follow-up for up to 36 months.

Results: The leptin-replacement therapy with the twice-daily injection dramatically improved fasting glucose (mean ± SE, 172 ± 20 to 120 ± 12 mg/dl, P < 0.05) and triglyceride levels (mean ± SE, 700 ± 272 to 260 ± 98 mg/dl, P < 0.05) within 1 wk. The leptin-replacement therapy reduced insulin resistance evaluated by euglycemic clamp method and augmented insulin secretion at glucose tolerance test with different responses between acquired and congenital types. Improvement of the fatty liver was also observed. The efficacy and safety of the once-daily injection were comparable to those of the twice-daily injection. The leptin-replacement therapy ameliorated macro- and microalbuminuria and showed no deterioration of neuropathy and retinopathy of these patients. The leptin-replacement therapy is beneficial to diabetic complications and lipodystrophic ones. Two patients developed antileptin antibodies but not neutralizing antibodies. The therapy was well tolerated, and its effects were maintained for up to 36 months without any notable adverse effects such as hypoglycemia, high blood pressure, or reduction of bone mineral density.

Conclusions: The present study demonstrates the efficacy and safety of the long-term leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.

This article has been cited by other articles:

				K. Takeuchi and K. Reue Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1195 - E1209. [Abstract] [Full Text] [PDF]

				C. S. Mantzoros Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome? J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1089 - 1091. [Full Text] [PDF]

				K. Mulligan, H. Khatami, J.-M. Schwarz, G. K. Sakkas, A. M. DePaoli, V. W. Tai, M. J. Wen, G. A. Lee, C. Grunfeld, and M. Schambelan The Effects of Recombinant Human Leptin on Visceral Fat, Dyslipidemia, and Insulin Resistance in Patients with Human Immunodeficiency Virus-Associated Lipoatrophy and Hypoleptinemia J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1137 - 1144. [Abstract] [Full Text] [PDF]

				S. McNear and S. A. Harrison Review: Current status of therapy in nonalcoholic fatty liver disease Therapeutic Advances in Gastroenterology, January 1, 2009; 2(1): 29 - 43. [Abstract] [PDF]

				G. Paz-Filho, K. Esposito, B. Hurwitz, A. Sharma, C. Dong, V. Andreev, T. Delibasi, H. Erol, A. Ayala, M.-L. Wong, et al. Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients Am J Physiol Endocrinol Metab, December 1, 2008; 295(6): E1401 - E1408. [Abstract] [Full Text] [PDF]

				J. Y. Park, A. Y. Chong, E. K. Cochran, D. E. Kleiner, M. J. Haller, D. A. Schatz, and P. Gorden Type 1 Diabetes Associated with Acquired Generalized Lipodystrophy and Insulin Resistance: The Effect of Long-Term Leptin Therapy J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 26 - 31. [Abstract] [Full Text] [PDF]